BCL2L1 and glioblastoma: Given that many glioblastoma lines overexpress the antiapoptotic proteins Bcl-2 or Bcl-XL [48,49], the ability of our derivatives to overcome this resistance checkpoint via Bax insertion may prove especially valuable in treating refractory tumors.